Skip to content

A clinical study to see the effect of some Ayurvedic formulations in the management of Mental Retardation.

Clinical Evaluation of Brahmi Ghrita and Jyotishmati Taila in the Management of Cognitive Deficit. - IMCRP-CDâ??2010-2011

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2012/03/002536
Enrollment
150
Registered
2012-03-30
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Cognitive Deficit

Interventions

Intervention1: Brahmi Ghrita along with Jyotishmati Taila: BRAHMI GHRITA-Dose â?? 10 gm twice daily
Duration of therapy-12 weeks AND JYOTISHMATI TAILA Dose â?? 2 drops twice daily
Route of Administration â?? Nasal
Packing form- 15 ml plastic bottle with dropper
Duration of therapy-12 weeks. Intervention2: Jyotishmati Taila: Dose â?? 2 drops twice daily Dosage form â?? Oil Route of Administration â?? Nasal Time of Administration-Twice a day Packing form- 15

Sponsors

Central Council for Research in Ayurvedic Sciences CCRAS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Children with Intelligence Quotient 70 - 84 (Weschlerâ??s-IQ Indian adaptation by Malin) 2. Willing and able to participate for 16 weeks. (Assent to be obtained from Parent(s) / Guardian(s)).

Exclusion criteria

Exclusion criteria: 1. Children suffering from major systemic illness necessitating long term drug treatment. 2. Children with evidence of malignancy. 3. Children with concurrent serious Hepatic Dysfunction (defined as AST and/or ALT > 3 times of the upper normal limit) or Renal Dysfunction (defined as S. creatinine > 1.2mg/dl) Uncontrolled Pulmonary Dysfunction (asthmatic and COPD patients) 4. H/o hypersensitivity to any of the trial drug or their ingredients 5. Children who have completed participation in any other clinical trial during the past six (06) months. 6. Any other condition which the P.I. thinks may jeopardize the study.

Design outcomes

Primary

MeasureTime frame
Symptomatic ImprovementTimepoint: At Baseline, 14th day-28th day-42nd day-56th day-70th day-84th day and at the end of follow up after 14th week

Secondary

MeasureTime frame
Change in Modified Child Mini Mental Scale Examination (MMMSE)Timepoint: At Baseline, 14th day-28th day-42nd day-56th day-70th day-84th day and at the end of follow up after 14th week

Countries

India

Contacts

Public ContactDr Pradeep Dua

Central Council for Research in Ayurvedic Sciences (CCRAS)

duadrpradeep@gmail.com011-28525831

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026